Header Logo

Connection

LEO LUZNIK to Drug Resistance, Neoplasm

Back to Details
This is a "connection" page, showing publications LEO LUZNIK has written about Drug Resistance, Neoplasm.
LEO LUZNIK
Connection Strength
0.035
Drug Resistance, Neoplasm
  1. Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Blood Cancer Discov. 2021 Nov; 2(6):616-629.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.